|

Camonsertib Clinical Trials

1 actively recruiting trial across 1 location

No change since March 2026

Also known as: ATR Inhibitor RP-3500, RP 3500, RP-3500, RP3500

Pipeline

Phase 1: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Unresectable Paranasal Sinus Squamous Cell Carcinoma1
  • Unresectable Oropharyngeal Squamous Cell Carcinoma1
  • Unresectable Oral Cavity Squamous Cell Carcinoma1
  • Unresectable Laryngeal Squamous Cell Carcinoma1
  • Unresectable Hypopharyngeal Squamous Cell Carcinoma1

Pittsburgh, Pennsylvania1 trial

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

UPMC Hillman Cancer Center LAO

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.